The increase in CD39 + CD8 + T cells in the TME is suggested as a potential mechanism involved in immunotherapy for EGFRmu NSCLC patients with third-generation EGFR-TKI acquired resistance. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.